Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 12/20 | 0.56 |
| ▸ | APP | P05067 | 4/20 | 0.51 |
| ▸ | BCHE | P06276 | 4/20 | 0.51 |
| ▸ | ACHE | P22303 | 4/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | WHR1 | P49842 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | ACACA | Q13085 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3941128 | 1.00 | NPY5R (0.56) | NPY5RAPPBCHEACHEADRA2A | |
| SCHEMBL14599452 | 0.89 | NPY5R (0.52) | NPY5RAPPBCHEACHEADRA2A | |
| SCHEMBL3947716 | 0.86 | MCHR1 (0.58) | NPY5RADRA2AMCHR1 | |
| SCHEMBL3947714 | 0.86 | MCHR1 (0.58) | NPY5RADRA2AMCHR1 | |
| SCHEMBL6630745 | 0.85 | CFD (0.45) | NPY5RAPPBCHEACHEACACB | |
| SCHEMBL6463065 | 0.84 | NPY5R (0.41) | NPY5RMCHR1 | |
| SCHEMBL6463063 | 0.84 | NPY5R (0.41) | NPY5RMCHR1 | |
| SCHEMBL6457102 | 0.82 | ACACB (0.43) | NPY5RACACBACACA | |
| SCHEMBL6457109 | 0.82 | ACACB (0.43) | NPY5RACACBACACA | |
| SCHEMBL13794051 | 0.80 | APP (0.45) | NPY5RAPPBCHEACHEADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544690-B2 | MCH receptor antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | MCHR1, MCHR2, MC4R | NPY5R 11/4885APP 3921/4885BCHE 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.